Scientists from National Taiwan University (NTU) and Linkou Chang Gung Memorial Hospital (CGMH) have made a significant advancement in the battle against glioblastoma (GBM), the most aggressive and deadly form of brain cancer. The complexity of treating glioblastoma is due to its invasive nature, the resilient blood-brain barrier (BBB), and a complicated tumor microenvironment. A critical aspect of this environment is the presence of cancer-associated fibroblasts (CAFs), which aid in tumor growth and can suppress the body's immune response.

A promising target for therapies is the fibroblast activation protein (FAP), which is abundantly expressed by both CAFs and glioblastoma cells. Recent research published in the journal Theranostics details a novel approach utilizing a precision-engineered nanoparticle to selectively deliver treatment to the tumor.

Development of the Trojan Horse

In their approach, the researchers have transformed natural ferritin into a highly specific drug carrier known as a ferritin-based drug carrier (FDC). Through the use of site-specific Sortase A-mediated ligation, a method that could be likened to a "molecular stapler," the team was able to attach an optimized FAP-targeting ligand to the surface of the ferritin shell. This modification maintains the natural structure of ferritin and allows it to encapsulate the potent cytotoxin monomethyl auristatin E (MMAE).

The engineered nanocage is designed to utilize ferritin's capability of binding to transferrin receptor 1 (TfR1), enabling the delivery of MMAE directly to both cancer cells and their supportive stromal components. This dual-targeting strategy represents a significant leap forward in glioblastoma therapy.

Mechanism of Action

The engineered carrier showcases remarkable specificity and efficacy in preclinical models. Key features of this approach include:

  • Pleasant Stability: The carrier remains stable in the bloodstream yet releases MMAE upon entering the tumor's acidic environment.
  • Increased Cellular Uptake: Compared to free MMAE, the nanocarrier markedly enhances drug uptake by target cells.
  • Minimized Systemic Toxicity: The targeted delivery mechanism ensures healthy brain tissue is largely spared from toxic effects.

Effects on Tumor Microenvironment

Further analysis utilizing spatial transcriptomic techniques and immunohistochemistry, has demonstrated that this innovative therapy does more than just kill tumor cells. It actively remodels the tumor microenvironment by:

  • Targeting CAFs: The approach attacks CAFs simultaneously with tumor cells, breaking down protective stroma.
  • Recruiting Cytotoxic Immune Cells: This modification helps mobilize immune cells into the tumor bed, turning a previously immunosuppressive environment into an active battlefield.
“Our approach acts like a guided missile combined with a Trojan Horse. By using a natural protein that already knows how to enter the brain, and adding our special tumor-finding radar, we can drop an exceptionally strong drug exactly where the cancer hides, leaving healthy areas completely safe.” – Yi-Hsiang Tseng, Lead Researcher

Future Directions

The research team aims to leverage the insights gleaned on the interaction between CAFs and immune dynamics in glioblastoma. Their objectives include:

  • Continuous optimization of the modular FDC platform for enhanced efficacy.
  • Integration of CAF-modulating technology with existing immunotherapies to develop comprehensive treatment paths.

According to Dr. Feng-Ting Huang, co-corresponding author and an associate professor at NTU, this platform represents a breakthrough in the treatment of glioblastoma.

Conclusion

This precision-engineered drug delivery system aims to provide real, transformative hope for patients by effectively targeting the glioblastoma's defenses and activating the body's natural immune response.

References

Yi-Hsiang Tseng et al. (2026). Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics, Theranostics.

Citation: Scientists engineer a 'Trojan Horse' to conquer aggressive brain cancer (2026, March 25) retrieved from Phys.org.